DE60036826D1 - Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs - Google Patents

Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs

Info

Publication number: DE60036826D1
Authority: DE; Germany
Prior art keywords: dexamethasone; cancer; treatment; combination therapy; therapy
Prior art date: 1999-05-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60036826T

Other languages

English (en)

Other versions

DE60036826T2 (de

Inventor

Esteban Cvitkovic

George Daniel Demetri

Cecilia Guzman

Jose Jimeno

Lazaro Luis Lopez

Jean-Louis Misset

Chris Twelves

Hoff Daniel D Von

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pharmamar SA

Original Assignee

Pharmamar SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-13

Filing date

2000-05-15

Publication date

2007-11-29

1999-05-13 Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en

1999-05-14 Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en

1999-08-05 Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en

1999-11-15 Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en

1999-11-16 Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en

2000-03-29 Priority claimed from GB0007637A external-priority patent/GB0007637D0/en

2000-05-15 Application filed by Pharmamar SA filed Critical Pharmamar SA

2007-11-29 Publication of DE60036826D1 publication Critical patent/DE60036826D1/de

2008-08-28 Application granted granted Critical

2008-08-28 Publication of DE60036826T2 publication Critical patent/DE60036826T2/de

2020-05-16 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)

DE60036826T 1999-05-13 2000-05-15 Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs Expired - Lifetime DE60036826T2 (de)

Applications Claiming Priority (12)

Application Number	Priority Date	Filing Date	Title
GBGB9911183.3A GB9911183D0 (en)	1999-05-13	1999-05-13	Treatment of cancers
GB9911183		1999-05-13
GB9911346		1999-05-14
GBGB9911346.6A GB9911346D0 (en)	1999-05-14	1999-05-14	Treatment of cancers
GBGB9918534.0A GB9918534D0 (en)	1999-08-05	1999-08-05	Treatment of cancers
GB9918534		1999-08-05
GBGB9927005.0A GB9927005D0 (en)	1999-11-15	1999-11-15	Treatment of cancers
GB9927005		1999-11-15
GBGB9927106.6A GB9927106D0 (en)	1999-11-16	1999-11-16	Cancer treatment
GB9927106		1999-11-16
GB0007637		2000-03-29
GB0007637A GB0007637D0 (en)	2000-03-29	2000-03-29	Antitumour compound

Publications (2)

Publication Number	Publication Date
DE60036826D1 true DE60036826D1 (de)	2007-11-29
DE60036826T2 DE60036826T2 (de)	2008-08-28

Family

ID=27546594

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DE60030554T Active DE60030554T8 (de)	1999-05-13	2000-05-15	Verwendungen von et743 zur behandlung von krebs
DE60036826T Expired - Lifetime DE60036826T2 (de)	1999-05-13	2000-05-15	Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
DE60045720T Expired - Lifetime DE60045720D1 (de)	1999-05-13	2000-05-15	Behandlung von Krebs beim Menschen mit ET743
DE122008000013C Pending DE122008000013I1 (de)	1999-05-13	2000-05-15	Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DE60030554T Active DE60030554T8 (de)	1999-05-13	2000-05-15	Verwendungen von et743 zur behandlung von krebs

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DE60045720T Expired - Lifetime DE60045720D1 (de)	1999-05-13	2000-05-15	Behandlung von Krebs beim Menschen mit ET743
DE122008000013C Pending DE122008000013I1 (de)	1999-05-13	2000-05-15	Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs

Country Status (32)

Country	Link
US (1)	US8119638B2 (de)
EP (3)	EP1176964B8 (de)
JP (2)	JP2002544231A (de)
KR (1)	KR20020019914A (de)
CN (2)	CN1360503A (de)
AR (1)	AR028476A1 (de)
AT (3)	ATE500830T1 (de)
AU (2)	AU777417B2 (de)
BG (1)	BG65680B1 (de)
BR (1)	BR0010531A (de)
CA (1)	CA2373794C (de)
CY (4)	CY1105818T1 (de)
CZ (1)	CZ301482B6 (de)
DE (4)	DE60030554T8 (de)
DK (3)	DK1702618T3 (de)
ES (2)	ES2272279T3 (de)
FR (1)	FR08C0013I2 (de)
HU (2)	HU229866B1 (de)
IL (2)	IL146434A0 (de)
LU (1)	LU91418I2 (de)
MX (1)	MXPA01011562A (de)
MY (1)	MY164077A (de)
NL (1)	NL300337I2 (de)
NO (2)	NO324564B1 (de)
NZ (1)	NZ515423A (de)
PL (1)	PL198185B1 (de)
PT (3)	PT1176964E (de)
SI (3)	SI1176964T1 (de)
SK (1)	SK287580B6 (de)
TR (1)	TR200103819T2 (de)
UA (1)	UA74782C2 (de)
WO (1)	WO2000069441A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY164077A (en)	1999-05-13	2017-11-30	Pharma Mar Sa	Compositions and uses of et743 for treating cancer
MXPA02011319A (es)	2000-05-15	2003-06-06	Pharma Mar Sa	Analogos antitumorales de ecteinascidina 743.
WO2002036135A2 (en) *	2000-11-06	2002-05-10	Pharma Mar, S.A.	Compositions for antitumour treatment containing ecteinascidin 743
GB0117402D0 (en) *	2001-07-17	2001-09-05	Pharma Mar Sa	New antitumoral derivatives of et-743
BR0213424A (pt) *	2001-10-19	2004-12-14	Pharma Mar Sa	Uso aperfeiçoado de composto antitumoral na terapia contra câncer
GB0202544D0 (en)	2002-02-04	2002-03-20	Pharma Mar Sa	The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) *	2003-05-29	2003-07-02	Pharma Mar Sau	Treatment
GB0324201D0 (en) *	2003-10-15	2003-11-19	Pharma Mar Sau	Improved antitumoral combinations
EP1689404B9 (de) *	2003-11-13	2009-04-22	Pharma Mar, S.A.U.	Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
EP1691809A1 (de) *	2003-11-14	2006-08-23	Pharma Mar, S.A.	Kombinationstherapie mit verwendung von et-743 und paclitaxel zur behandlung von krebs
GB0326486D0 (en) *	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
NZ552607A (en) *	2004-07-09	2009-07-31	Pharma Mar Sa	Prognostic molecular markers
US20090117176A1 (en) *	2004-10-26	2009-05-07	Pharma Mar, S.A. Sociedad Unipersonal	Anticancer Treatments
NZ554761A (en)	2004-10-29	2010-01-29	Pharma Mar Sa	Formulations comprising ecteinascidin and a disaccharide
GB0522082D0 (en) *	2005-10-31	2005-12-07	Pharma Mar Sa	Formulations
WO2007134203A2 (en) *	2006-05-12	2007-11-22	Pharma Mar, S.A.	Anticancer treatments with a combination of docetaxel and ecteinascidin
JP2011500046A (ja) *	2007-10-19	2011-01-06	ファルマ・マール・ソシエダード・アノニマ	Ｅｔ−７４３治療のための予後分子マーカー
JP2019504061A (ja) *	2016-02-04	2019-02-14	ジエンスヘンルイメデイシンカンパニーリミテッドＪｉａｎｇｓｕＨｅｎｇｒｕｉＭｅｄｉｃｉｎｅＣｏ．，Ｌｔｄ．	トラベクテジンの注射可能な胃腸外用医薬組成物及びその製造方法
JOP20190254A1 (ar)	2017-04-27	2019-10-27	Pharma Mar Sa	مركبات مضادة للأورام
WO2020239478A1 (en)	2019-05-28	2020-12-03	Pharma Mar, S.A.	Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) *	2019-09-27	2022-05-24	江苏恒瑞医药股份有限公司	一种海鞘素衍生物的制备方法
JP7715732B2 (ja)	2020-04-15	2025-07-30	エバーバリンジェクトゲーエムベーハー	トラベクテジンおよびアミノ酸を含む組成物
EP3960177A1 (de) *	2020-08-26	2022-03-02	Anturec Pharmaceuticals GmbH	Zusammensetzung mit ttf-ngr zur verwendung in der behandlung von weichgewebesarkom
US12303506B2 (en)	2022-01-20	2025-05-20	Extrovis Ag	Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5256663A (en) *	1986-06-09	1993-10-26	The Board Of Trustees Of The University Of Illinois	Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) *	1990-11-30	1992-09-22	The Board Of Trustees Of The University Of Illinois	Ecteinascidins 736 and 722
FI885726A7 (fi) *	1986-06-09	1988-12-09	Univ Of Illinois	Ekteinaskidiinit 729, 743, 745, 759A, 759B ja 770
US5089273A (en) *	1986-06-09	1992-02-18	Board Of Trustees Of The University Of Illinois	Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (de) *	1986-10-21	1988-04-28	Knoll Ag	5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) *	1988-03-04	1988-04-07	Glaxo Group Ltd	Medicaments
GB9101221D0 (en) *	1991-01-19	1991-02-27	Smithkline Beecham Plc	Pharmaceuticals
US5721352A (en)	1991-02-19	1998-02-24	University Of Florida Research Foundation	Entomopoxvirus expression system
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) *	1992-11-19	1999-04-06	Anticancer, Inc.	Method to produce high levels of methioninase
WO1994026250A1 (en) *	1993-05-14	1994-11-24	Depotech Corporation	Method for treating neurological disorders
US5478932A (en) *	1993-12-02	1995-12-26	The Board Of Trustees Of The University Of Illinois	Ecteinascidins
US20040059112A1 (en) *	1994-02-18	2004-03-25	Rinehart Kenneth L.	Ecteinascidins
US5919816A (en) *	1994-11-14	1999-07-06	Bionumerik Pharmaceuticals, Inc.	Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en) *	1995-04-20	1995-06-07	Univ British Columbia	Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) *	1996-09-18	1998-02-24	President And Fellows Of Harvard College	Process for producing ecteinascidin compounds
EP1586322B1 (de) *	1996-11-05	2008-08-20	The Children's Medical Center Corporation	Zusammensetzungen enthaltend Thalidomide und Dexamethason für die Behandlung von Krebs
IL123740A0 (en) *	1997-03-28	1998-10-30	Pfizer	NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) *	1997-04-15	1999-11-16	Univ Illinois	Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) *	1997-05-15	1998-11-19	Hoechst Ag	Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) *	1997-06-05	1998-03-18	Merck & Co Inc	A method of treating cancer
KR100603219B1 (ko) *	1998-04-06	2006-07-20	더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈	반합성 엑테이나시딘
AU759281B2 (en) *	1998-05-11	2003-04-10	Pharma Mar S.A.	Metabolites of ecteinascidin 743
US6124292A (en) *	1998-09-30	2000-09-26	President And Fellows Of Harvard College	Synthetic analogs of ecteinascidin-743
MY164077A (en)	1999-05-13	2017-11-30	Pharma Mar Sa	Compositions and uses of et743 for treating cancer
AR035842A1 (es)	1999-05-14	2004-07-21	Pharma Mar Sa	Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
JP5219323B2 (ja)	2000-04-12	2013-06-26	ファルマ・マール・ソシエダード・アノニマ	抗腫瘍性エクチナサイジン誘導体
US7247892B2 (en) *	2000-04-24	2007-07-24	Taylor Geoff W	Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) *	2000-05-15	2008-09-02	Pharma Mar, S.A.	Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) *	2000-05-15	2003-06-06	Pharma Mar Sa	Analogos antitumorales de ecteinascidina 743.
CA2418320A1 (en) *	2000-08-11	2002-02-21	City Of Hope	The anti-neoplastic agent et-743 inhibits trans activation by sxr
WO2002036135A2 (en)	2000-11-06	2002-05-10	Pharma Mar, S.A.	Compositions for antitumour treatment containing ecteinascidin 743
WO2002064843A1 (en)	2001-02-09	2002-08-22	The Regents Of The University Of California	Ecteinascidin family compounds: compositions and methods
WO2002078678A2 (en)	2001-03-30	2002-10-10	Shire Biochem Inc.	Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en)	2001-09-03	2001-10-24	Cancer Res Ventures Ltd	Anti-cancer combinations
BR0213424A (pt)	2001-10-19	2004-12-14	Pharma Mar Sa	Uso aperfeiçoado de composto antitumoral na terapia contra câncer
US20040019027A1 (en) *	2002-04-12	2004-01-29	Barry Forman	Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) *	2003-05-29	2003-07-02	Pharma Mar Sau	Treatment
GB0324201D0 (en) *	2003-10-15	2003-11-19	Pharma Mar Sau	Improved antitumoral combinations
EP1689404B9 (de)	2003-11-13	2009-04-22	Pharma Mar, S.A.U.	Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
GB0326486D0 (en) *	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
EP1691809A1 (de) *	2003-11-14	2006-08-23	Pharma Mar, S.A.	Kombinationstherapie mit verwendung von et-743 und paclitaxel zur behandlung von krebs
NZ552607A (en) *	2004-07-09	2009-07-31	Pharma Mar Sa	Prognostic molecular markers
CN101068596A (zh) *	2004-09-29	2007-11-07	法马马私人股份有限公司	艾可特耐思地作抗炎药
US20090117176A1 (en) *	2004-10-26	2009-05-07	Pharma Mar, S.A. Sociedad Unipersonal	Anticancer Treatments
NZ554761A (en) *	2004-10-29	2010-01-29	Pharma Mar Sa	Formulations comprising ecteinascidin and a disaccharide
EP1962843B1 (de) *	2005-11-25	2011-02-23	Pharma Mar S.A., Sociedad Unipersonal	Verwendung von parp-1-hemmern
WO2007134203A2 (en) *	2006-05-12	2007-11-22	Pharma Mar, S.A.	Anticancer treatments with a combination of docetaxel and ecteinascidin

2000
- 2000-05-13 MY MYPI20002107A patent/MY164077A/en unknown
- 2000-05-15 UA UA2001128559A patent/UA74782C2/uk unknown
- 2000-05-15 ES ES00927584T patent/ES2272279T3/es not_active Expired - Lifetime
- 2000-05-15 EP EP00927584A patent/EP1176964B8/de not_active Expired - Lifetime
- 2000-05-15 EP EP06014005A patent/EP1716853B9/de not_active Expired - Lifetime
- 2000-05-15 AR ARP000102321A patent/AR028476A1/es not_active Application Discontinuation
- 2000-05-15 WO PCT/GB2000/001857 patent/WO2000069441A1/en not_active Ceased
- 2000-05-15 PT PT00927584T patent/PT1176964E/pt unknown
- 2000-05-15 DK DK06011784T patent/DK1702618T3/da active
- 2000-05-15 PT PT06011784T patent/PT1702618E/pt unknown
- 2000-05-15 MX MXPA01011562A patent/MXPA01011562A/es active IP Right Grant
- 2000-05-15 CZ CZ20014081A patent/CZ301482B6/cs not_active IP Right Cessation
- 2000-05-15 DE DE60030554T patent/DE60030554T8/de active Active
- 2000-05-15 DK DK06014005.0T patent/DK1716853T3/da active
- 2000-05-15 JP JP2000617900A patent/JP2002544231A/ja not_active Withdrawn
- 2000-05-15 CA CA002373794A patent/CA2373794C/en not_active Expired - Lifetime
- 2000-05-15 AT AT06014005T patent/ATE500830T1/de active
- 2000-05-15 AT AT00927584T patent/ATE338552T1/de active
- 2000-05-15 TR TR2001/03819T patent/TR200103819T2/xx unknown
- 2000-05-15 HU HU0201187A patent/HU229866B1/hu active Protection Beyond IP Right Term
- 2000-05-15 CN CN00809976A patent/CN1360503A/zh active Pending
- 2000-05-15 KR KR1020017014479A patent/KR20020019914A/ko not_active Ceased
- 2000-05-15 NZ NZ515423A patent/NZ515423A/en not_active IP Right Cessation
- 2000-05-15 DE DE60036826T patent/DE60036826T2/de not_active Expired - Lifetime
- 2000-05-15 PT PT06014005T patent/PT1716853E/pt unknown
- 2000-05-15 PL PL352931A patent/PL198185B1/pl unknown
- 2000-05-15 AT AT06011784T patent/ATE375795T1/de active
- 2000-05-15 SK SK1644-2001A patent/SK287580B6/sk not_active IP Right Cessation
- 2000-05-15 DK DK00927584T patent/DK1176964T3/da active
- 2000-05-15 ES ES06011784T patent/ES2294756T3/es not_active Expired - Lifetime
- 2000-05-15 DE DE60045720T patent/DE60045720D1/de not_active Expired - Lifetime
- 2000-05-15 AU AU45975/00A patent/AU777417B2/en not_active Expired
- 2000-05-15 BR BR0010531-7A patent/BR0010531A/pt not_active Application Discontinuation
- 2000-05-15 DE DE122008000013C patent/DE122008000013I1/de active Pending
- 2000-05-15 SI SI200030905T patent/SI1176964T1/sl unknown
- 2000-05-15 SI SI200031067T patent/SI1716853T1/sl unknown
- 2000-05-15 IL IL14643400A patent/IL146434A0/xx active IP Right Grant
- 2000-05-15 SI SI200030977T patent/SI1702618T1/sl unknown
- 2000-05-15 CN CNB2005100091622A patent/CN100477993C/zh not_active Expired - Lifetime
- 2000-05-15 EP EP06011784A patent/EP1702618B1/de not_active Expired - Lifetime
2001
- 2001-11-11 IL IL146434A patent/IL146434A/en active Protection Beyond IP Right Term
- 2001-11-12 NO NO20015516A patent/NO324564B1/no not_active IP Right Cessation
- 2001-12-03 BG BG106171A patent/BG65680B1/bg unknown
2005
- 2005-01-14 AU AU2005200180A patent/AU2005200180B9/en not_active Expired
2006
- 2006-11-30 CY CY20061101734T patent/CY1105818T1/el unknown
2007
- 2007-06-28 US US11/769,873 patent/US8119638B2/en not_active Expired - Fee Related
2008
- 2008-01-16 CY CY20081100059T patent/CY1107143T1/el unknown
- 2008-02-22 NL NL300337C patent/NL300337I2/nl unknown
- 2008-03-10 LU LU91418C patent/LU91418I2/fr unknown
- 2008-04-07 CY CY200800007C patent/CY2008007I2/el unknown
- 2008-04-16 FR FR08C0013C patent/FR08C0013I2/fr active Active
- 2008-05-16 NO NO2008005C patent/NO2008005I1/no not_active IP Right Cessation
2011
- 2011-06-08 CY CY20111100545T patent/CY1112753T1/el unknown
2012
- 2012-05-02 JP JP2012105249A patent/JP5777562B2/ja not_active Expired - Lifetime
2015
- 2015-01-06 HU HUS1500001C patent/HUS1500001I1/hu unknown

Also Published As

Publication number	Publication date
ES2294756T3 (es)	2008-04-01
CN1360503A (zh)	2002-07-24
FR08C0013I2 (fr)	2009-10-30
ES2272279T3 (es)	2007-05-01
US20070275942A1 (en)	2007-11-29
SK287580B6 (sk)	2011-03-04
AU4597500A (en)	2000-12-05
NO2008005I2 (de)	2010-09-27
US8119638B2 (en)	2012-02-21
TR200103819T2 (tr)	2002-04-22
IL146434A0 (en)	2002-07-25
DE122008000013I1 (de)	2008-08-07
DE60045720D1 (de)	2011-04-21
EP1702618A2 (de)	2006-09-20
CN1679631A (zh)	2005-10-12
HU229866B1 (en)	2014-10-28
SI1702618T1 (sl)	2008-02-29
EP1716853A2 (de)	2006-11-02
LU91418I9 (de)	2019-01-02
AU2005200180B9 (en)	2008-05-29
HUP0201187A3 (en)	2002-11-28
EP1716853B9 (de)	2011-09-28
CY1107143T1 (el)	2010-07-28
CY1112753T1 (el)	2016-02-10
PT1716853E (pt)	2011-05-12
EP1176964B8 (de)	2007-10-10
CZ301482B6 (cs)	2010-03-17
BG65680B1 (bg)	2009-06-30
PT1176964E (pt)	2007-01-31
CZ20014081A3 (cs)	2002-11-13
CA2373794A1 (en)	2000-11-23
EP1176964B1 (de)	2006-09-06
PT1702618E (pt)	2008-01-11
EP1716853B1 (de)	2011-03-09
WO2000069441A1 (en)	2000-11-23
AU2005200180B2 (en)	2007-12-13
NO20015516D0 (no)	2001-11-12
MY164077A (en)	2017-11-30
EP1702618A3 (de)	2006-12-27
NO324564B1 (no)	2007-11-19
HUP0201187A2 (en)	2002-09-28
JP2002544231A (ja)	2002-12-24
BG106171A (en)	2002-06-28
CY2008007I1 (el)	2009-11-04
SI1176964T1 (sl)	2007-02-28
DK1702618T3 (da)	2008-02-25
NL300337I2 (nl)	2008-09-01
CY2008007I2 (el)	2009-11-04
DE60030554T8 (de)	2008-01-10
NO2008005I1 (no)	2008-06-09
EP1176964A1 (de)	2002-02-06
UA74782C2 (uk)	2006-02-15
CN100477993C (zh)	2009-04-15
AU2005200180A1 (en)	2005-02-10
DE60030554D1 (de)	2006-10-19
NL300337I1 (nl)	2008-05-01
FR08C0013I1 (de)	2008-05-30
BR0010531A (pt)	2002-06-04
NO20015516L (no)	2002-01-11
PL352931A1 (en)	2003-09-22
AU777417B2 (en)	2004-10-14
SK16442001A3 (sk)	2002-03-05
IL146434A (en)	2008-03-20
CY1105818T1 (el)	2011-02-02
DE60030554T2 (de)	2007-09-13
HUS1500001I1 (hu)	2016-08-29
JP5777562B2 (ja)	2015-09-09
ATE375795T1 (de)	2007-11-15
SI1716853T1 (sl)	2011-10-28
NZ515423A (en)	2004-04-30
KR20020019914A (ko)	2002-03-13
AR028476A1 (es)	2003-05-14
ATE338552T1 (de)	2006-09-15
MXPA01011562A (es)	2002-07-30
LU91418I2 (fr)	2008-05-13
EP1702618B1 (de)	2007-10-17
PL198185B1 (pl)	2008-06-30
CA2373794C (en)	2005-10-11
DE60036826T2 (de)	2008-08-28
ATE500830T1 (de)	2011-03-15
EP1716853A3 (de)	2006-11-15
DK1176964T3 (da)	2007-01-15
JP2012149095A (ja)	2012-08-09
DK1716853T3 (da)	2011-06-27

Publication	Publication Date	Title
DE60036826D1 (de)	2007-11-29	Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
DE69941566D1 (de)	2009-12-03	N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
EP1080113A4 (de)	2002-04-17	Behandlung von humanen tumoren mit bestrahlung und inhibitoren der wachstumsfaktorrezeptor-tyrosinkinase
DE60019555D1 (de)	2005-05-25	2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60032226D1 (de)	2007-01-18	Verfahren zur induktion von krebszellentod und tumorregression
ATE275145T1 (de)	2004-09-15	Chinazolinderivate zur behandlung von tumoren
ATE400283T1 (de)	2008-07-15	Reovirus zur behandlung von zellulären proliferativen erkrankungen
DE60028358D1 (de)	2006-07-06	Hmg1 antagonisten zur behandlung von entzündungen
DE60037394D1 (de)	2008-01-24	VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DE60026704D1 (de)	2006-05-11	(S,S)-Reboxetine zur Behandlung chronischer Schmerzen
ATE271038T1 (de)	2004-07-15	4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE60023816D1 (de)	2005-12-15	Verwendung von Lycopin in Zusammensetzungen zur Behandlung von Hautalterungs-Erscheinungen
DE60229959D1 (de)	2009-01-02	Kombinationstherapie zur behandlung von krebs
DE60038458D1 (de)	2008-05-08	Verwendung von polymerem material zur behandlung harter oberflächen
DE60027429D1 (de)	2006-05-24	Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE60018200D1 (de)	2005-03-24	Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE59704933D1 (de)	2001-11-22	Verwendung von PHMB zur Behandlung von Tumorerkrankungen
ATE290866T1 (de)	2005-04-15	Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
DE59002772D1 (de)	1993-10-28	Verwendung von Dextransulfat, gegebenenfalls in Kombination mit anti-androgenen Mitteln zur Behandlung des humanen Protatakarzinoms.
DE60112423D1 (de)	2005-09-08	Verwendung von substituierten distamycin-acryloylderivaten zur behandlung von tumoren die mit erhöhten glutathion-spiegeln zusammenhängen
DE50011084D1 (de)	2005-10-06	Verwendung von azolen zur prävention von strahlen-induziertem hautkrebs
NO20014228D0 (no)	2001-08-31	Radioaktiv cisplatin i behandling av cancer
DE69934336D1 (de)	2007-01-18	Verwendung von halofuginone zur behandlung von urethralstriktur
DE69935156D1 (de)	2007-03-29	hCG THERAPIE ZUR BEHANDLUNG VON METASTATISCHEM BRUSTKREBS
ATE420074T1 (de)	2009-01-15	Bengamide-derivate und deren verwendung zur behandlung von krebserkrankungen

Legal Events

Date	Code	Title	Description
2008-04-03	V448	Application of spc	Free format text: PRODUCT NAME: YONDELIS-TRABECTEDIN; REGISTRATION NO/DATE: EU/1/07/417/001, EU/1/07/417/002; 20070917 Spc suppl protection certif: 12 2008 000 013 Filing date: 20080403
2008-06-26	8327	Change in the person/name/address of the patent owner	Owner name: PHARMA MAR, S.A., COLMENAR VIEJO, MADRID, ES
2008-07-10	8381	Inventor (new situation)	Inventor name: DEMETRI, GEORGE DANIEL, BOSTON, MASS., US Inventor name: GUZMAN, CECILIA, COLMENAR VIEJO, MADRID, ES Inventor name: JIMENO, JOSE, COLMENAR VIEJO, MADRID, ES Inventor name: LOPEZ LAZARO, LUIS, COLMENAR VIEJO, MADRID, ES Inventor name: MISSET, JEAN-LOUIS, VILLEJUIF CEDEX, FR Inventor name: TWELVES, CHRIS, BEARSDEN GLASGOW, ES Inventor name: VON HOFF, DANIEL D., TUCSON, ARIZ., US Inventor name: CVITKOVIC, ESTEBAN, 94278 LE KREMLIN-BICETRE, FR
2008-11-06	8364	No opposition during term of opposition
2016-08-03	R067	Examining division decision granting supplementary protection certificate	Free format text: PRODUCT NAME: YONDELIS-TRABECTEDIN; REGISTRATION NO/DATE: EU/1/07/417/001-002 20070917 Spc suppl protection certif: 122008000013 Filing date: 20080403 Expiry date: 20200516 Extension date: 20220920
2016-09-09	R069	Supplementary protection certificate granted	Free format text: PRODUCT NAME: YONDELIS-TRABECTEDIN; REGISTRATION NO/DATE: EU/1/07/417/001-002 20070917 Spc suppl protection certif: 122008000013 Filing date: 20080403 Expiry date: 20200516 Extension date: 20220920